SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer

Journal of Pathology

Volumn 229, Issue 1, 2013, Pages 12-24

  Wang, Feng ^a   Ma, Yan Lei ^a   Zhang, Peng ^a   Shen, Tong Yi ^a   Shi, Chen Zhang ^b   Yang, Yong Zhi ^b   Moyer, Mary Pat ^c   Zhang, Hui Zhen ^b   Chen, Hong Qi ^b   Liang, Yong ^b   Qin, Huan Long ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c INCELL Corporation ^*  (United States)

Author keywords

CRC; epigenetic silencing; miR 149; overall survival; promoter methylation; Sp1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; MESSENGER RNA; MICRORNA; MICRORNA 149; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; EPIGENETIC REPRESSION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE;

AZACITIDINE; BASE SEQUENCE; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HCT116 CELLS; HT29 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION;

EID: 84872836602     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4078     Document Type: Article

References (70)

1. Center MM, Jemal A, Smith RA, et al., Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-378.
2. Herman JG, Umar A, Polyak K, et al., Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95: 6870-6875.
3. Kim MS, Lee J, Sidransky D,. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010; 29: 181-206.
4. van Engeland M, Derks S, Smits KM, et al., Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 2011; 29: 1382-1391.
5. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002; 3: 415-428.
6. Zhang B, Pan X, Cobb GP, et al., microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
7. Michael MZ, O'Connor SM, van Holst Pellekaan NG, et al., Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891.
8. Slaby O, Svoboda M, Michalek J, et al., MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
9. Farazi TA, Spitzer JI, Morozov P, et al., miRNAs in human cancer. J Pathol 2011; 223: 102-115.
10. Weber B, Stresemann C, Brueckner B, et al., Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007; 6: 1001-1005.
11. Lujambio A, Ropero S, Ballestar E, et al., Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429.
12. Toyota M, Suzuki H, Sasaki Y, et al., Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68: 4123-4132.
13. Grady WM, Parkin RK, Mitchell PS, et al., Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008; 27: 3880-3888.
14. Bandres E, Agirre X, Bitarte N, et al., Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-2743.
15. Balaguer F, Link A, Lozano JJ, et al., Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010; 70: 6609-6618.
16. Kamimae S, Yamamoto E, Yamano HO, et al., Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev Res (Phila) 2011; 4; 674-683.
17. Kalimutho M, Di Cecilia S, Del Vecchio Blanco G, et al., Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer 2011; 104: 1770-1778.
18. Wang H, Wu J, Meng X, et al., MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 2011; 32: 1033-1042.
19. Tang JT, Wang JL, Du W, et al., MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011; 32: 1207-1215.
20. Moyer MP, Manzano LA, Merriman RL, et al., NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 1996; 32: 315-317.
21. Zhao D, Keates AC, Kuhnt-Moore S, et al., Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001; 276: 44464-44471.
22. Rhee I, Bachman KE, Park BH, et al., DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556.
23. Sobin LH,. TNM Classification of Malignant Tumours (UICC). 6th edn. Wiley-Liss: New York, 2002.
24. Beahrs OH,. Colorectal cancer staging as a prognostic feature. Cancer 1982; 50: 2615-2617.
25. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
26. Jiang L, Mao P, Song L, et al., miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 2010; 177: 29-38.
27. Daskalakis M, Nguyen TT, Nguyen C, et al., Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2964.
28. Liew CT, Li HM, Lo KW, et al., High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999; 18: 789-795.
29. Doench JG, Petersen CP, Sharp PA,. siRNAs can function as miRNAs. Genes Dev 2003; 17: 438-442.
30. Xiao F, Zuo Z, Cai G, et al., miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37: D105-D110.
31. Tchernitsa O, Kasajima A, Schafer R, et al., Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol 2010; 222: 310-319.
32. Nair VS, Maeda LS, Ioannidis JP,. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012; 104: 528-540.
33. Schepeler T, Reinert JT, Ostenfeld MS, et al., Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424.
34. Lu J, Getz G, Miska EA, et al., MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
35. Diaz R, Silva J, Garcia JM, et al., Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008; 47: 794-802.
36. Schetter AJ, Leung SY, Sohn JJ, et al., MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. J Am Med Assoc 2008; 299: 425-436.
37. Sotiropoulou G, Pampalakis G, Lianidou E, et al., Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 2009; 15: 1443-1461.
38. Denis H, Ndlovu MN, Fuks F,. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2011; 12: 647-656.
39. Christman JK,. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-5495.
40. Hu Z, Chen J, Tian T, et al., Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008; 118: 2600-2608.
41. Hu Z, Liang J, Wang Z, et al., Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat 2009; 30: 79-84.
42. Liu Z, Li G, Wei S, et al., Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer 2010; 116: 4753-4760.
43. Mw Z, Mj J, Yx Y, et al., Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk. Mol Carcinog 2011.
44. Sun G, Yan J, Noltner K, et al., SNPs in human miRNA genes affect biogenesis and function. RNA 2009; 15: 1640-1651.
45. Vinci S, Gelmini S, Pratesi N, et al., Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med 2011; 49: 2073-2080.
46. Ng EK, Chong WW, Jin H, et al., Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381.
47. Liu H, Brannon AR, Reddy AR, et al., Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 2010; 4: 51.
48. Wong TS, Liu XB, Wong BY, et al., Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14: 2588-2592.
49. Schaefer A, Jung M, Mollenkopf HJ, et al., Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-1176.
50. Li D, Chen P, Li XY, et al., Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I-III astrocytomas. OMICS 2011; 15: 673-682.
51. Ushijima T,. Epigenetic field for cancerization. J Biochem Mol Biol 2007; 40: 142-150.
52. Shen L, Kondo Y, Rosner GL, et al., MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97: 1330-1338.
53. Kadonaga JT, Carner KR, Masiarz FR, et al., Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987; 51: 1079-1090.
54. Suske G,. The Sp-family of transcription factors. Gene 1999; 238: 291-300.
55. Bouwman P, Philipsen S,. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 2002; 195: 27-38.
56. Safe S, Abdelrahim M,. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-2448.
57. Hosoi Y, Watanabe T, Nakagawa K, et al., Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 2004; 25: 461-468.
58. Kitadai Y, Yasui W, Yokozaki H, et al., The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Biochem Biophys Res Commun 1992; 189: 1342-1348.
59. Lietard J, Musso O, Theret N, et al., Sp1-mediated transactivation of LamC1 promoter and coordinated expression of laminin-gamma1 and Sp1 in human hepatocellular carcinomas. Am J Pathol 1997; 151: 1663-1672.
60. Chiefari E, Brunetti A, Arturi F, et al., Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2002; 2: 35.
61. Shi Q, Le X, Abbruzzese JL, et al., Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 4143-4154.
62. Kumar AP, Butler AP,. Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 1999; 137: 159-165.
63. Wang L, Wei D, Huang S, et al., Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003; 9: 6371-6380.
64. Yao JC, Wang L, Wei D, et al., Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10: 4109-4117.
65. Ishibashi H, Nakagawa K, Onimaru M, et al., Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000; 60: 6531-6536.
66. Abdelrahim M, Samudio I, Smith R 3rd, et al., Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 2002; 277: 28815-28822.
67. Lou Z, O'Reilly S, Liang H, et al., Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005; 65: 1007-1017.
68. Kanai M, Wei D, Li Q, et al., Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res 2006; 12: 6395-6402.
69. Luo Z, Zhang L, Li Z, et al., An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics 2012; 5: 3.
70. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nature Rev Cancer 2006; 6: 857-866.